interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Aripiprazole Lauroxil

Generic competition · all medicines · read 12 November 2026

Is there a generic of Aripiprazole Lauroxil, and who makes it?

Aripiprazole Lauroxil appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Aripiprazole Lauroxil1 dosage-form group in the Orange Book
0generic makers listed
  1. Aripiprazole Lauroxil appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Suspension, Extended Release, Intramuscular

Brand listed, no generic listed as marketed

Brand listed as marketed: Aristada and Aristada Initio Kit. No generic is listed as marketed.

20152020202520302035204001brand 2015data datePatent 10112903 listed to expire 24 June 2030Patent 8796276 listed to expire 24 June 2030Patent 8431576 listed to expire 26 October 2030Patent 10226458 listed to expire 19 March 2032Patent 9034867 listed to expire 7 November 2032Patent 12629366 listed to expire 6 December 2032Patent 11097006 listed to expire 19 September 2033Patent 12311027 listed to expire 19 September 2033Patent 9193685 listed to expire 24 October 2033Patent 11969469 listed to expire 6 April 2034Patent 10238651 listed to expire 19 March 2035Patent 9452131 listed to expire 19 March 2035Patent 10813928 listed to expire 19 March 2035Patent 11406632 listed to expire 19 March 2035Patent 12653822 listed to expire 19 March 2035Patent 9526726 listed to expire 19 March 2035Patent 10849894 listed to expire 17 August 2035Patent 11154552 listed to expire 17 August 2035Patent 10688091 listed to expire 17 August 2035Patent 10016415 listed to expire 8 September 2035Patent 12251381 listed to expire 6 April 2039Patent 11273158 listed to expire 6 April 2039
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 24 June 2030Patent 10112903 drug substance
  • 24 June 2030Patent 8796276
  • 26 October 2030Patent 8431576 drug substance
  • 19 March 2032Patent 10226458
  • 7 November 2032Patent 9034867 drug product
  • 6 December 2032Patent 12629366 drug product
  • 19 September 2033Patent 11097006 drug product
  • 19 September 2033Patent 12311027 drug product

14 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.